Bauer R, Dobesberger J, Unterhofer C, Unterberger I, Walser G, Bauer G, Trinka E, Ortler M
Clinical Department of Neurosurgery, Innsbruck Medical University, Innsbruck, Austria.
Acta Neurochir (Wien). 2007 Dec;149(12):1211-6; discussion 1216-7. doi: 10.1007/s00701-007-1366-z. Epub 2007 Oct 22.
Tumours are a well-recognized cause of medically intractable epilepsies. Tumours represent the primary pathology in 10%-30% of patients undergoing surgical treatment for chronic epilepsy. This study examines the surgical and epileptological outcome of adults with temporal lobe tumoural epilepsy treated within a comprehensive epilepsy surgery programme.
Between 1999 and 2004, 99 consecutive patients have been operated for intractable temporal lobe epilepsy (TLE). Among these, 14 adult patients exhibited temporal lobe neoplasms associated with TLE. Every patient underwent a comprehensive presurgical evaluation including video-EEG monitoring, MRI, interictal PET scan, ictal SPECT and neuropsychological testing. Surgical strategies were determined in an interdisciplinary seizure conference and tailored to the findings of the presurgical evaluation. All patients were available for follow up at regular intervals after 3, 6, 12 months and yearly thereafter. Epileptological outcome was classified according to Engel [10] and the ILAE (International League Against Epilepsy)/systems [33].
The surgical procedures performed were temporal lobe resection in 3 patients, extended lesionectomy in 4 and extended lesionectomy with resection of the temporomesial structures in 7. One patient with an astrocytoma grade III underwent a second and third operation for recurrent disease. Histological results: Astrocytoma 5 patients, ganglioglioma/gangliocytoma 5, oligodendroglioma 2, ependymoma 1 and dysembryoplastic neuroepithelial tumour (DNET) 1. Postoperative follow-up was performed after 12-74 months (mean 31). The outcome according to the Engel classification indicated class IA in 9 patients, class IC in 3, and 1 each in classes IIIA and IVA. Epileptological outcome according to the ILAE classification indicated class 1 (12 patients) and class 4 (2 patients). Surgical mortality was zero and mild permanent neurological deficits due to surgery were seen in 2 patients. Postoperatively 3 patients showed a homonymous quadrantanopia.
Patients with drug resistant epilepsy and temporal lobe tumours should undergo evaluation in dedicated epilepsy surgery programmes.
肿瘤是医学上难治性癫痫的一个公认病因。在接受慢性癫痫手术治疗的患者中,肿瘤是10%-30%患者的主要病理原因。本研究探讨了在综合癫痫手术项目中接受治疗的成人颞叶肿瘤性癫痫患者的手术及癫痫学结局。
1999年至2004年间,99例连续患者接受了难治性颞叶癫痫(TLE)手术。其中,14例成年患者表现出与TLE相关的颞叶肿瘤。每位患者均接受了全面的术前评估,包括视频脑电图监测、MRI、发作间期PET扫描、发作期SPECT和神经心理学测试。手术策略在多学科癫痫发作会议上确定,并根据术前评估结果进行调整。所有患者在术后3、6、12个月定期随访,此后每年随访一次。癫痫学结局根据Engel[10]和国际抗癫痫联盟(ILAE)/系统[33]进行分类。
实施的手术程序包括3例颞叶切除术、4例扩大性病灶切除术和7例扩大性病灶切除术并切除颞叶内侧结构。1例III级星形细胞瘤患者因疾病复发接受了第二次和第三次手术。组织学结果:星形细胞瘤5例,神经节细胞胶质瘤/神经节细胞瘤5例,少突胶质细胞瘤2例,室管膜瘤1例,胚胎发育不良性神经上皮肿瘤(DNET)1例。术后随访12-74个月(平均31个月)。根据Engel分类,结局为IA级9例,IC级3例,IIIA级和IVA级各1例。根据ILAE分类,癫痫学结局为1级(12例)和4级(2例)。手术死亡率为零,2例患者出现因手术导致的轻度永久性神经功能缺损。术后3例患者出现同向象限盲。
耐药性癫痫和颞叶肿瘤患者应在专门的癫痫手术项目中接受评估。